Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Abingdon Health shares are trading higher on Tuesday after the company launched a score-card product available alongside its AbC-19 rapid test.
The score-card “provides a semi-quantitative result to indicate the strength of antibody response and possible immunity.”
The test produces a line when it detects IgG neutralising antibodies to the spike protein of COVID-19, which are produced both after vaccination and natural infection.
The intensity of the line, which can be seen visually, is proportional to the amount of these IgG neutralising antibodies present in the finger-prick blood sample, with higher levels of antibodies producing a stronger test line.
Abingdon said using the score-card accessory alongside AbC-19TM LFD will allow scientific communities to help further understand the presence and strength of IgG neutralising antibodies following infection and/or vaccination.
The company is also in the process of preparing the CE-marking of this score-card accessory for the AbC-19.
Chris Yates, CEO of Abingdon Health, said: “The launch of the semi-quantitative accessory to AbC-19™ is an important addition to the tools available to researchers as they qualify and measure the antibody level appropriate to infer protective immunity.
“There is a lot of work underway internationally to set a globally recognised standard threshold and we welcome the establishment of an international standard that will help governments manage their vaccine and booster programmes. Devices such as the AbC-19™ help democratise testing and allow individuals to know their own neutralising antibody status, assess their own risk, and seek appropriate advice when indicated.”
Abingdon's share price is currently trading at 50.2p, up 7.98%, erasing Monday's 5.1% loss.
Abingdon Health shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Abingdon Health shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .